Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Last traded Jan 15, 2026. This price is not current.
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
Dated clinical, regulatory and corporate events for Semler Scientific, Inc.
How SMLR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
No drug pipeline
Semler Scientific, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Readouts, endpoints and source filings for every SMLR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Murphy-Chutorian DouglasDirector, Officer (CEO, interim CFO and Director) | Option | 125,000 125,000 held | $2.23 | 11/17/2025 |
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Opaleye Management Inc. | 1.1 % (-66.7 %) | 3.47 M | 70.00 K | -59.3% ( -102.00 K) |
Shares sold short, counted twice a month.
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
How SMLR ranks across every disease it competes in